Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 28

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Ischaemic stroke

Recruiting

Comparison of General Anesthesia versus High-Flow Nasal Cannula Sedation in Patients with Acute Ischemic Stroke Undergoing Endovascular Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Fentanyl Citrate
  • Sponsor:Hospital Universitario La Paz

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Study on Rituximab for Achieving Remission in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Amsterdam UMC Stichting

Neurogenic bladder

Recruiting

Study on E. coli Polysaccharide for Reducing Antibiotic Use in Patients with Neurogenic Bladder and Recurrent Urinary Tract Infections

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:E.coli Polysaccharide
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Ischaemic stroke

Recruiting

Study on the Effects of Mepivacaine Hydrochloride for Patients with Neurological Symptoms After Ischemic Stroke

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mepivacaine Hydrochloride
  • Sponsor:Assistance Publique Hopitaux De Paris

Infant sedation

Recruiting

Study on Sedation Effects of Dexmedetomidine vs. Midazolam in Mechanically Ventilated Preterm Infants

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Midazolam
  • Sponsor:Assistance Publique Hopitaux De Paris

Glioblastoma multiforme

Recruiting

Long-term safety study of Temferon (modified stem cells with interferon-α2) in patients previously treated for glioblastoma multiforme

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Autologous Cd34+ Haematopoietic Stem And Progenitor Cells Transduced With A Lentiviral Vector Encoding The Interferon Alpha-2 Gene
  • Sponsor:Genenta Science S.p.A.

Neurofibromatosis

Recruiting

Study on Crizotinib for Treating Severe Neurofibromatosis Type 2 in Children Not Eligible for Surgery or Radiotherapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Crizotinib
  • Sponsor:Medical University Of Warsaw

Multiple sclerosis

Recruiting

Study on Stopping Dimethyl Fumarate and Drug Combination in Patients Aged 55+ with Inactive Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dimethyl Fumarate
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Craniocerebral injury

Recruiting

Study on the Effects of Cerebrolysin and Sodium Chloride for Recovery in Patients with Moderate to Severe Traumatic Brain Injury

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Foundation For The Study Of Nanoneuroscience And Neuroregeneration

Angelman's syndrome

Recruiting

Study on the Safety and Effects of ION582 for Patients with Angelman Syndrome

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:2'-O-(2-Methoxyethyl) Modified Antisense Oligonucleotide Targeting Ube3A Antisense Transcript Rna
  • Sponsor:Ionis Pharmaceuticals Inc.

Parkinson's disease

Recruiting

Study on Amantadine for Reducing Motor Fluctuations in Advanced Parkinson's Disease Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amantadine Hydrochloride
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Atrial fibrillation+2

Recruiting

Study on Aspirin and Clopidogrel for Patients with Atrial Fibrillation After Left Atrial Appendage Closure

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Clopidogrel
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.